| Phase 4 |
| NCT07498205 |
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low… |
SWOG Cancer Research Network |
Not Yet Recruiting |
2026-08-28 |
| NCT02386800 |
CINC424A2X01B Rollover Protocol |
Novartis Pharmaceuticals |
Active, Not Recruiting |
2026-08-20 |
| Phase 3 |
| NCT07357727 |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Novartis Pharmaceuticals |
Recruiting |
2026-09-01 |
| NCT07623161 |
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are… |
Takeda |
Recruiting |
2026-08-24 |
| NCT04064060 |
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… |
Celgene |
Recruiting |
2026-07-01 |
| NCT06351631 |
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) |
Merck Sharp & Dohme LLC |
Recruiting |
2026-04-02 |
| NCT05198960 |
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic… |
University Hospital, Brest |
Recruiting |
2026-03-20 |
| NCT06479135 |
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With… |
Kartos Therapeutics, Inc. |
Recruiting |
2025-09-25 |
| NCT06468033 |
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk |
PharmaEssentia |
Active, Not Recruiting |
2026-08-13 |
| NCT04603495 |
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) |
Novartis Pharmaceuticals |
Active, Not Recruiting |
2026-07-17 |
| NCT04717414 |
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With… |
Celgene |
Active, Not Recruiting |
2026-07-16 |
| NCT04576156 |
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of… |
Geron Corporation |
Active, Not Recruiting |
2026-07-08 |
| NCT03165734 |
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia… |
Swedish Orphan Biovitrum |
Active, Not Recruiting |
2026-04-30 |
| NCT04562389 |
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis |
Karyopharm Therapeutics Inc |
Active, Not Recruiting |
2026-04-09 |
| NCT04468984 |
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best… |
AbbVie |
Active, Not Recruiting |
2026-01-09 |
| Phase 2/3 |
| NCT07539779 |
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With… |
Nanfang Hospital, Southern Medical University |
Not Yet Recruiting |
2026-04-20 |
| Phase 2 |
| NCT06661915 |
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… |
National Cancer Institute (NCI) |
Recruiting |
2026-09-01 |
| NCT06345495 |
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients… |
M.D. Anderson Cancer Center |
Recruiting |
2026-08-20 |
| NCT07228624 |
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With… |
Fred Hutchinson Cancer Center |
Recruiting |
2026-08-19 |
| NCT07394153 |
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have… |
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas |
Recruiting |
2026-07-28 |
| NCT04370301 |
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or… |
Fred Hutchinson Cancer Center |
Recruiting |
2026-07-20 |
| NCT07551427 |
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105… |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recruiting |
2026-07-15 |
| NCT05805605 |
Allo HSCT Using RIC and PTCy for Hematological Diseases |
Masonic Cancer Center, University of Minnesota |
Recruiting |
2026-07-06 |
| NCT03314974 |
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
Masonic Cancer Center, University of Minnesota |
Recruiting |
2026-06-25 |
| NCT05835466 |
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium… |
Icahn School of Medicine at Mount Sinai |
Recruiting |
2026-05-06 |